Keyes Stange & Wooten Wealth Management LLC increased its stake in Daxor Co. (NASDAQ:DXR – Free Report) by 34.8% in the third quarter, Holdings Channel reports. The institutional investor owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC’s holdings in Daxor were worth $126,000 as of its most recent SEC filing.
Daxor Price Performance
Shares of DXR opened at $9.28 on Friday. Daxor Co. has a 1 year low of $7.11 and a 1 year high of $10.04. The firm has a fifty day moving average of $9.03 and a 200-day moving average of $9.02.
Wall Street Analyst Weigh In
Separately, Ascendiant Capital Markets lifted their price objective on shares of Daxor from $24.50 to $24.75 and gave the stock a “buy” rating in a report on Monday, September 9th.
Daxor Company Profile
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Further Reading
- Five stocks we like better than Daxor
- Stock Market Upgrades: What Are They?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 11/18 – 11/22
- Compound Interest and Why It Matters When Investing
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Want to see what other hedge funds are holding DXR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Daxor Co. (NASDAQ:DXR – Free Report).
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
